Comparison of the effect of letrozole alone with letrozole plus n-acetylcysteine on pregnancy rate in patients with polycystic ovarian syndrome: A randomized clinical trial by Teimouri, B. et al.
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/348644308
Comparison of the Effect of Letrozole Alone With Letrozole Plus N-
Acetylcysteine on Pregnancy Rate in Patients With Polycystic Ovarian
Syndrome: A Randomized Clinical Trial
















All content following this page was uploaded by Farahnaz - Farzaneh on 27 January 2021.
The user has requested enhancement of the downloaded file.
Abstract
Objectives: Different drugs are prescribed for the induction of ovulation in patients with polycystic ovary syndrome (PCOS). The aim 
of this study was to compare the effect of letrozole alone with letrozole plus N-acetyl cysteine (NAC) on the pregnancy rate in patients 
with PCOS.
Materials and Methods: This clinical trial studyincluded317 patients with PCOS in the infertility clinic of Zahedan in 2018. Patients 
were randomly divided into letrozole and NAC plus letrozole groups. Then, several parameters were evaluated in both groups, 
including the pregnancy rate, number of follicles larger than 18 mm, endometrial thickness, and the endometrial pattern. Finally, data 
were analyzed using SPSS 25, and t-test and chi-square tests were used for statistical analysis.
Results: The mean age of study participants was 28.5 ± 4.9 years old. The mean duration of infertility in the intervention group was 4.5 
± 3.8 years. The mean anti-Müllerian hormone and the mean endometrial thickness of patients in the intervention group were 4.4± 
3.6 ng/mL and 7.6 ± 2.5 mm, respectively. Eventually, the pregnancy rate was 14.6% (n = 23) and 7.5% (n = 12) in the intervention 
and control groups, respectively (P = 0.046).
Conclusions: The results of this search revealed that the number of follicles with the size of 18 mm in the control group was higher 
compared to the intervention group, but the fertility rate in patients with PCOS receiving letrozole plus N-acetylcysteine was 
significantly higher.
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Introduction
Infertility is characterized by the inability to obtain 
a successful pregnancy after 6 months or more with 
unprotected and regular intercourse. In developing 
countries, the incidence of infertility is 2%. The causes 
of infertility could be a male or female factor or a mixed 
factor. About 2, 40, and 2% of infertility problems are 
related to a male, female, and mixed factor, respectively (1-
3). The most common female cause is ovulatory disorders 
(40-35%). Polycystic ovary syndrome (PCOS) is the most 
common cause of ovulation disorders (4).
According to the World Health Organization 
classification, endocrine dysfunction is the second most 
common functional disorder in women of childbearing 
age that includes hyperandrogenism and ovulation 
disorder. Many patients with PCOS (50%-75%) develop 
insulin resistance. These patients suffer from infertility, 
which is mainly due to the lack of ovulation (5,6).
Additionally, PCOS is the most common endocrine 
disorder in women and the most common cause of 
infertility due to oligo ovulation or anovulation. In 
addition, it affects 5-10% of women of reproductive age 
according to the National Institutes of Health/National 
Institute of Child Health and Human Development 
criteria. According to the latest definition in 2003 
(Rotterdam Criterion), PCOS has at least two criteria 
of three quantitative criteria, including the amount of 
menstrual bleeding (oligo menorrhea or amenorrhea), 
the clinical or biochemical symptoms of increased male 
hormones and sonographic findings suggesting polycystic 
ovary.
Furthermore, fertility problems such as infertility, 
bleeding caused by dysfunction, endometrial carcinoma, 
and postmenopausal menopause are more common in 
patients with PCOS depression, low self-esteem, anxiety, 
and metabolic disorders such as obesity, impaired 
glucose tolerance, type 2 diabetes, lipid disorders, and 
hypertension suffer (7-9).
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 ► Previous evidence demonstrates the effect of NAC on 
reducing semen viscosity and even as a supplement and 
its positive effects. Considering the fact that a significant 
percentage of infertility is due to hyperandrogenism and 
anovulation, the usefulness of this drug considering its 
availability and lesser side effects will be effective.
Key Messages
The incidence of PCOS varies between 2.2 and 26% in 
different countries. The reason for the difference in the 
prevalence of PCOS is because the clinical characteristics 
and biochemical characteristics of these patients may 
differ according to race and ethnicity (6). Moreover, the 
prevalence of PCOS may differ with age and community. 
The incidence of PCOS seems to be higher in young 
women compared to those over 35 years of age (5,10,11).
PCOS is considered to be a complex trait arising from 
the interaction of genetic and environmental factors, 
which is usually first presented when mature gonadotropin 
levels are achieved at puberty. It occurs naturally in non-
human primates and humans. The pathogenesis of PCOS 
can be envisioned according to a ‘two-hit” hypothesis, 
whereby the disorder arises as a congenitally programmed 
predisposition (first hit) that manifests in the presence of 
a provocative factor (second hit).
The congenital factors can be either hereditary (genetic) 
or acquired (e.g., maternal drugs or nutritional disorders 
affecting the fetus). The postnatal provocative factor is 
typically insulin-resistant hyperinsulinism, which may 
have been congenitally programmed and/or acquired 
postnatally due to simple (exogenous) obesity.
These complex interactions generally mimic an 
autosomal dominant pattern of inheritance with variable 
penetrance. The heritability of PCOS has been estimated 
at over 70% based on studies in identical twin sisters (10).
Currently, the first applied drug for induction ovulation 
in patients with the endocrine syndrome is estrogen 
receptor modulator clomiphene citrate as an estrogen 
receptor modulator, and its success rate has been reported 
in various cases. Clomiphene citrate resistance is found 
in 15%-20% of patients that ovulation does not persist 
after standard drug therapy, therefore, finding strategies 
to increase the success of induction ovulation in infertile 
patients has great importance.
Other proposed drugs for the induction of ovulation 
in patients with PCOS may include aromatase inhibitors, 
including letrozole, which, like clomiphene reduces the 
hypothalamic-pituitary-axis estrogenic stimulation by 
decreases estrogen biosynthesis. One of the benefits of 
letrozole is the lower probability of multiple pregnancies 
and greater endometrial thickness at the end of the 
treatment. It also has a half-life of about 45 hours and has 
less adverse effects on estrogen target tissues such as the 
endometrium and cervix compared to clomiphene (10).
Letrozole as the first-line treatment for ovulation 
induction can be as effective as clomiphene. In some 
studies, letrozole has a success rate of 70%-84% in 
ovulation induction, 20%-27% pregnancy rate, and 
endometrial thickness after treatment with letrozole has 
been reported 7-9 mm (5,10).
Other studies have shown that insulin sensitivity 
enhancers decrease the levels of hyperandrogenism and 
hypertension in patients with PCOS and are effective in 
induction ovulation in these patients (10, 12).
Another suggested drug for the induction of ovulation 
is N-acetyl cysteine (NAC). It is an acetylated derivative 
of L-cysteine and is safe, inexpensive, and affordable. 
In addition, it is a great source of sulfhydryl groups and 
converts into metabolites that stimulate glutathione 
production and increase detoxification and directly 
decompose free reactive oxygen species (12).
NAC also has an effect on insulin release in beta cells 
in the pancreas and regulates insulin receptors on human 
erythrocytes (13). Effects such as lowering serum androgen 
levels and improving homocysteine status and lipid profile 
have also been reported in patients with PCOS (14).
Previous evidence demonstrates the effect of NAC on 
reducing semen viscosity and even as a supplement and 
its positive effects. Considering the fact that a significant 
percentage of infertility is due to hyperandrogenism and 
anovulation, the usefulness of this drug considering its 
availability and lesser side effects will be effective.
Therefore, this study was performed to investigate 
the inducible effect of NAC on letrozole in ovulation 
induction in infertile women with PCOS.
Materials and Methods
This clinical trial study was performed on 317 patients 
with PCOS referring to the infertility clinic of Zahedan 
in 2018. Patients were selected based on two criteria of 
the three main criteria (oligo/anovulation), clinical or 
laboratory evidence of hyperandrogenism, polycystic 
ovary morphology on ultrasound (Rotterdam criteria), 
normality of thyroid function and prolactin, normal 
semen analysis, at least one year of infertility, and the 
existence of at least one patient tube. On the other hand, the 
exclusion criteria were thyroid dysfunction and prolactin, 
tubal or uterine disorders leading to infertility, moderate 
and severe oligozoospermia, asthenozoospermia, and 
teratozoospermia, size of an ovarian cyst greater than 6 
cm, history of asthma, and any drug affecting glucose 
metabolism.
Patients were randomly divided into control (letrozole 
alone) and intervention (letrozole NAC plus). It was 
impossible to be blinded in this study because patients 
did not visit simultaneously and were unaware of the 
treatment of others. There was virtually no placebo.
The control group was selected from patients with 
the same inclusion criteria and standard treatment of 
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letrozole were visited by the same infertility fellowship on 
different days. Totally, the variables were small and no bias 
was possible.
The control group received 5 mg of letrozole daily 
for day 5 and the intervention group received 5 mg of 
letrozole 5 mg daily with 1200 mg NAC for 5 days. The 
patients’ medicines were obtained from a factory.
Five days after the last dose of letrozole, patients 
underwent a vaginal ultrasound to measure endometrial 
thickness, as well as the number and diameter of mature 
follicles. The ultrasound of the patients was performed 
by one infertility fellowship using an ultrasound device. 
In the presence of at least one follicle equal to or greater 
than 18 mm, 5000 units of human chorionic gonadotropin 
(HCG) were injected intramuscularly and intercourse was 
recommended approximately 12, 36, and 60 hours after 
the injection. 
On the 12th day after HCG injection, serum beta-
HCG levels were measured to check for pregnancy. 
The ovulation and pregnancy rates in each group were 
calculated and finally compared as well.
Statistical Analysis
The central and dispersion indices were used to describe 
the quantitative data, and frequency distribution tables 
(absolute and relative) were employed to describe the 
qualitative data. T test and the nonparametric test were 
used to analyze quantitative data for normal and abnormal 
data, respectively. The data were analyzed by SPSS version 
25.
Results
The mean age of patients was 28.5 ± 4.9 years (P = 0.441). 
The mean BMI was 25.9 ± 4.3 kg/m2 and 26.6 ± 5.7 kg/
m2 in intervention and control groups, respectively. 
The mean duration of infertility in the intervention and 
control groups was 4.5 ± 3.8 years and 4.3 ± 2.9 years (P = 
0.713), respectively (Table 1).
The mean AMH was 4.4 ± 3.6 ng/mL and 5.1 ± 2.5 ng/
mL in the intervention and control groups, respectively 
(P = 0.200). In addition, 75 (47.5%) follicles larger than 
18 mm and 83 (52.5%) follicles smaller than 18 mm were 
observed in the intervention group while 96 (60.4%) cases 
had follicles larger than 18 mm and 63 (39.6%) of them 
had follicles smaller than 18 mm in the control group, 
this difference was statistically significant (P = 0.021). 
In the present study, the pregnancy rate was 23 patients 
(14.6%) in the intervention group, and 12 (7.5%) cases 
were pregnant in the control group and this difference was 
statistically significant (P = 0.046) as well (fellowchart1). 
Endometrial thickness was 7.6± 2.5 mm and 7.9 ± 2.7 
mm in the intervention and control groups, respectively, 
representing no statistically significant difference between 
the two groups (P = 0.333). In the present study, 18 
(11.4%) and 140 (88.6%) patients had a homogeneous 
endometrial pattern and three-line endometrial pattern in 
Table 1. Comparison of Primary Variables in the 2 Study Groups
Variable
Group




Age 28.2 ± 5.0 28.7 ± 4.8 0.441
BMI 25.9 ± 4.3 26.6 ± 5.7 0.251
Duration of infertility 4.5 ± 3.8 4.3 ± 2.9 0.713
Note. BMI, Body mass index; NAC, N-acetyl cysteine.
Table 2. Comparison of Studied Variables Between the 2 Groups
Variable
Group




AMH 4.4±3.6 5.1±5.2 0.200
Follicle >18 mm 75 (47.5%) 96 (60.4%) 0.021
Pregnancy rate 23 (14.6%) 12 (7.5%) 0.046
Endometrial thickness (mm) 7.6±2.5 7.9±2.7 0.333
Note. AMH, Anti-Müllerian hormone; NAC, N-acetyl cysteine.
the intervention group, respectively. In the control group, 
15 (9.4%) cases had a homogenous endometrial pattern 
and 144 (90.6%) of them had a three-layer endometrial 
pattern. This difference was not statistically significant 
(P = 0.556), the details of which are presented in Table 2.
Discussion 
Infertility in women with PCOS is a serious problem 
and there are various ways to increase their pregnancy 
rate. Letrozole significantly increases the probability of 
pregnancy in patients with the polycystic ovary, but the 
success rate in this procedure is not precisely known and 
reaches 20% in the best cases (15). On the other hand, 
Kilic‐Okman and Kucuk described NAC as an effective 
drug in lowering serum insulin and testosterone while 
improving the serum homocysteine level and lipid profile 
in PCOS patients (14). Pregnancy rates were assessed 
in patients with PCOS. This study evaluated the effect 
of NAC on letrozole for pregnancy rate in patients with 
PCOS.
The results of our study showed that the pregnancy rate 
was 14.6% and 7.5% in intervention and control groups, 
respectively, and follicles larger than 18 mm were observed 
in the intervention (47.5%) and control (60.4%) groups, 
showing the significant effect of NAC on increasing 
fertility in these patients (Figure 1).
In their study, Mostajeran et al divided 130 PCOS 
patients into letrozole plus NAC and letrozole alone and 
represented that ovulation and pregnancy rates were 
significantly higher in the letrozole plus NAC group, 
which is consistent with our study, but unlike our study, 
the number of follicles greater than 18 mm was also 
significant in the letrozole plus NAC group (15).
In line with the findings of our study, Holzer et al found 
that the success rate of letrozole in ovulation induction 
was 70%-84%, and the pregnancy rates of 20%-27%were 
observed and finally, endometrial thickness was between 
Teimouri et al
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7 and 9 mm (10).
Based on the results of a study by Dabbaghi Ghale et 
al on 40 women with PCOS, NAC failed to increase the 
success rate of letrozole in induction ovulation in these 
women, and the pregnancy rate was observed in 15% and 
20% of the control and intervention groups, respectively. 
Similar to our study, the fertility rate was higher in the 
intervention group and was statistically significant. 
Furthermore, the mean endometrial thickness was 
similar to our study in the two groups although the mean 
number of follicles in the intervention group was higher in 
comparison with the control group (16). 
Other studies also used clomiphene and NAC. For 
example, Riyahi Nezhad et al reported that adding NAC 
to clomiphene significantly increased the follicle size 
and pregnancy rate in women (17). In a similar study 
by Salehpour et al, 167 infertile women with PCOS 
were randomly treated with clomiphene, NAC plus 
clomiphene, and placebo (17)and the results revealed that 
ovulation and pregnancy rates were significantly higher 
in the clomiphene plus NAC groups compared to the 
clomiphene and placebo groups (18).
In the study of Badawy et al, ovulation rate and 
endometrial thickness were reported after a cycle of 
treatment with clomiphene and NAC significantly higher 
than before. The observed mean follicles after NAC were 
also significantly higher (19).
Other studies compared the effect of clomiphene and 
NAC with clomiphene alone for the induction of ovulation 
in patients with unexplained infertility. Patients were 
compared in two groups receiving clomiphene alone and 
clomiphene with NAC. Based on their findings, ovulation 
rate and endometrial thickness were significantly higher 
than before with a clomiphene and NAC cycle. Finally, 
the mean follicles observed after NAC were significantly 
higher (20, 21).
Conclusions
The findings of our study and other studies showed that 
the addition of NAC to letrozole, similar to clomiphene, 
increases the fertility rate in women with PCOS and 
promotes the success of infertility.
Study Limitations
The optimal therapeutic effects of NAC may be limited to 
a specific range of patients, therefore, it is recommended 
to conduct studies on patients with high BMI, insulin-
resistant, or clomiphene-resistant patients although it is 
not feasible due to the limited cost of university approval. 
Eventually, studies with higher doses of NAC or longer 
evaluations may give more hope for the efficacy of this 
drug in ovulation, which requires further studies.
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Pregnancy rate = 23 (14.6%) 
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Figure 1. Comparison of Pregnancy Rate and Follicle Size Between the Two Groups.
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